1-3 of 3
Ying Poi Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Recombinant Factor IX-FIAV and Bypassing Agents in Thrombin Generation Analyses in Hemophilia A Patient Plasma: The FIVITAS Study

Lorenzo G.R. Romano, Viola J.F. Strijbis, Ka Lei Cheung, Ying Poi Liu, Andrew C. McCreary, Frank W.G. Leebeek, Mettine H.A. Bos
Journal: Blood
Blood (2021) 138 (Supplement 1): 3192.
https://doi.org/10.1182/blood-2021-150492
Published: 2021
Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1110.
https://doi.org/10.1182/blood-2019-124120
Published: 2019
Journal Articles

Predictable Protein Expression with Enhanced Factor IX Activity Following Administration of a Modified AAV5-hFIX Vector to Nonhuman Primates

Ying Poi Liu, PhD, Jacek Lubelski, PhD, Erich Ehlert, PhD, Sander Gielen, PhD, Paula Miranda, PhD, Martin de Haan, Bart Nijmeijer, PhD, Harald Petry, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2058.
https://doi.org/10.1182/blood.V130.Suppl_1.2058.2058
Published: 2017